Roche Holding AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)
- Conditions
- Colorectal Cancer
- Interventions
- Other: BevacizumabCombination Product: Chemotherapy
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT02305615
- Locations
- ๐ญ๐บ
Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary
๐ญ๐บSzent Margit Hospital, Budapest, Hungary
๐ญ๐บSemmelweis Egyetem Onkologiai Kรถzpont, Budapest, Hungary
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT02304393
- Locations
- ๐ฉ๐ฐ
Rigshospitalet; Onkologisk Klinik, Kรธbenhavn ร, Denmark
๐จ๐ฆUniversity Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
๐จ๐ฆJewish General Hospital / McGill University, Montreal, Quebec, Canada
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 931
- Registration Number
- NCT02302807
- Locations
- ๐ท๐ธ
Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
๐ฌ๐งBarts and The London, London, United Kingdom
๐จ๐ฆTom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada
A Study of RG7625 in Healthy Volunteers
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT02295332
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
- Conditions
- Colorectal Cancer
- Interventions
- Drug: FOLFOX induction regimenDrug: Fluoropyrimidine (5-FU/LV or capecitabine)Drug: 5-FU/LV
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1044
- Registration Number
- NCT02291289
- Locations
- ๐ฆ๐ท
Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncologรญa, Buenos Aires, Argentina
๐ง๐ชInstitut Jules Bordet X, Brussels, Belgium
๐ง๐ชHospital Erasme, Bruxelles, Belgium
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT02289833
- Locations
- ๐ต๐ฑ
Medical University of Gdansk, Gdansk, Poland
๐ต๐ฑMazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland
๐จ๐ญCHUV; Departement d'Oncologie, Lausanne, Switzerland
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice
- Conditions
- Colorectal Cancer
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT02287597
- Locations
- ๐ญ๐ท
Clinical Hospital Osijek; Dept For Oncology & Radiotherapy, Osijek, Croatia
๐ญ๐ทUni Hospital Split; Oncology & Radiotherapy, Split, Croatia
๐ญ๐ทUni Hospital For Tumours; Dept of Medical Oncology, Zagreb, Croatia
An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 510
- Registration Number
- NCT02286362
- Locations
- ๐ซ๐ท
CROM, Osny, France
๐ซ๐ทC H Du Pays D'Aix En Provence; Hopital De Jour, Aix En Provence, France
๐ซ๐ทClinique Du Docteur Calabet; Cromg, Agen, France
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02286089
A Study of RO6926496 in Healthy Volunteers
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT02281786